Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 16/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.59 |
| ▸ | CASP1 | P29466 | 2/20 | 0.59 |
| ▸ | CASP7 | P55210 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30616279 | 1.00 | ALDH1A1 (0.59) | ALDH1A1HSD17B10CASP1CASP7MAPK1 | |
| SCHEMBL6004820 | 0.90 | ALDH1A1 (0.58) | ALDH1A1HSD17B10CASP1CASP7MAPK1 | |
| SCHEMBL30905509 | 0.89 | ALDH1A1 (0.59) | ALDH1A1HSD17B10CASP1CASP7MAPK1 | |
| SCHEMBL30905503 | 0.89 | ALDH1A1 (0.59) | ALDH1A1HSD17B10CASP1CASP7MAPK1 | |
| SCHEMBL17137179 | 0.89 | ALDH1A1 (0.51) | ALDH1A1HSD17B10CASP1CASP7MAPK1 | |
| SCHEMBL21200952 | 0.86 | ALDH1A1 (0.56) | ALDH1A1HSD17B10CASP1CASP7MAPK1 | |
| SCHEMBL374339 | 0.84 | ALDH1A1 (0.67) | ALDH1A1HSD17B10CASP1CASP7MAPK1 | |
| SCHEMBL1890105 | 0.84 | ALDH1A1 (0.59) | ALDH1A1HSD17B10CASP1CASP7MAPK1 | |
| SCHEMBL6431438 | 0.84 | ALDH1A1 (0.62) | ALDH1A1HSD17B10CASP1CASP7MAPK1 | |
| SCHEMBL21200929 | 0.83 | ALDH1A1 (0.58) | ALDH1A1HSD17B10CASP1CASP7MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4647127-A2 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | Exelixis, Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| EP-3743070-B1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | EXELIXIS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| CN-117820226-A | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-117624045-A | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-117603138-A | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-02-27 | — | — | CN | disclosed |
| US-20240043414-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2024-02-08 | — | — | US | disclosed |
| CN-117402114-A | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-111757735-B | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2023-09-22 | — | — | CN | disclosed |
| US-11542259-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20210040076-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2021-02-11 | — | — | US | disclosed |
| WO-2019148044-A1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | EXELIXIS, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
| WO-2019148044-A1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | EXELIXIS, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
| US-7973164-B2 | Quinoline derivatives | ASTRAZENECA AB (SE) | 2011-07-05 | — | — | US | disclosed |
| US-20090076075-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| US-20090076074-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| EP-1994024-A2 | QUINOLINE DERIVATIVES | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | disclosed |
| EP-1994025-A1 | QUINOLINE DERIVATIVES | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007099323-A2 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007099326-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-07 | — | — | WO | disclosed |
| EP-1724268-A1 | COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076075-A1 | QUINOLINE DERIVATIVES | RECQL, NQO2, NRAS | ALDH1A1 832/4885HSD17B10 3921/4885CASP1 1938/4885 |
| US-11542259-B2 | Compounds for the treatment of kinase-dependent disorders | ERBB2, MAP3K6, MAP3K1 | ALDH1A1 3310/4885HSD17B10 3135/4885CASP1 3102/4885 |
| US-20210040076-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | ERBB2, MAP3K6, MAP3K1 | ALDH1A1 3310/4885HSD17B10 3135/4885CASP1 3102/4885 |
| US-20090076074-A1 | QUINOLINE DERIVATIVES | RECQL, NQO2, CCNA1 | ALDH1A1 887/4885HSD17B10 3699/4885CASP1 1915/4885 |
| US-20240043414-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | ERBB2, MAP3K6, MAP3K1 | ALDH1A1 3310/4885HSD17B10 3135/4885CASP1 3102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.